Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio. Show more

Location: 6555 Carnegie Avenue, Cleveland, OH, 44103, United States | Website: https://www.abeonatherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

356.4M

52 Wk Range

$3.93 - $7.54

Previous Close

$6.95

Open

$6.95

Volume

277,114

Day Range

$6.77 - $7.00

Enterprise Value

155.5M

Cash

225.5M

Avg Qtr Burn

-16.49M

Insider Ownership

5.78%

Institutional Own.

73.56%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.